Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 332
- Registration Number
- NCT05899621
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05896163
- Locations
- 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇺🇸The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas, United States
🇺🇸The University of Kansas Clinical Research Center, Fairway, Kansas, United States
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT05894447
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York, United States
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT05861050
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 284
- Registration Number
- NCT05848765
- Locations
- 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧NHS Grampian, Aberdeen, United Kingdom
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 59
- Registration Number
- NCT05846750
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tian, China
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group
- Target Recruit Count
- 42
- Registration Number
- NCT05833763
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Sir Charles Gairdener, Nedlands, Western Australia, Australia
Rituximab in Combination with Glofitamab and Polatuzumab Vedotin in Patients with Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 125
- Registration Number
- NCT05798156
- Locations
- 🇦🇹
Uniklinik Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinikum Magdeburg, Magdeburg, Sachsen-Anhalt, Germany
🇩🇪Uniklinikum Düsseldorf, Düsseldorf, Germany
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Target Recruit Count
- 20
- Registration Number
- NCT05797948
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Reid Merryman, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05783596
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.